Bladder cancer fine typing method and system based on aptamer difference analysis
Through the method based on the differential analysis of nucleic acid aptamers, sequencing data and differentially expressed aptamers are obtained and processed, which solves the problem of precise typing of bladder cancer, achieves more detailed and accurate typing, and improves the personalization of the treatment plan and the accuracy of diagnosis.
Patent Information
- Application Number
- CN202411769306.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-12-04
- Publication Date
- 2025-03-28
- Estimated Expiration
- 2044-12-04
AI Technical Summary
The prior art is difficult to achieve precise typing of bladder cancer, and the nucleic acid aptamer of a single marker is not sufficient to cope with the high heterogeneity of bladder cancer.
By obtaining sequencing data, abnormal samples are removed and standardized, differential expression aptamers are selected, and the samples to be tested are then typed. Specific steps include high-throughput gene sequencing, standardization of nucleic acid aptamer data, and selection of differentially expressed aptamer.
The fine segmentation of bladder cancer cells has been achieved, the ability to identify tumor cells has been improved, and important support has been provided for the development of personalized treatment plans, reducing the possibility of misdiagnosis and missed diagnosis, and improving the accuracy of diagnosis.